Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Elanco Animal Health Incorporated (ELAN) vs Haleon PLC Sponsored ADR (HLN)

Elanco Animal Health Incorporated and Haleon PLC Sponsored ADR are both Drug Manufacturers Specialty & Generic companies. Haleon PLC Sponsored ADR is the larger, with a market value of $40.3B against $11.2B — 3.6× the size. Elanco Animal Health Incorporated has negative trailing earnings, so its P/E is not meaningful; Haleon PLC Sponsored ADR trades at 20.6×. Haleon PLC Sponsored ADR has the higher net margin (13.8% vs −3.96%) and the lower return on invested capital (0.00% vs 0.51%). Across the 20 metrics below, Haleon PLC Sponsored ADR leads on 13 and Elanco Animal Health Incorporated on 7.

Valuation

Metric ELAN HLN Drug Manufacturers Specialty & Generic median
P/E n/m 20.64 20.14
P/S 2.22 2.35 2.25
P/B 1.69 1.93 1.90
Price to free cash flow 31.22 9.36 16.54
EV/EBITDA 18.78 12.36 12.29
EV/Sales 2.89 2.90 2.56
Earnings yield (1.84%) 4.84% (2.99%)
Free cash flow yield 3.20% 10.68% 0.00%

Profitability

Metric ELAN HLN Drug Manufacturers Specialty & Generic median
Gross margin 55.36% 62.22% 53.94%
Operating margin 1.61% 17.93% 0.00%
Net margin (3.96%) 13.79% 0.00%
Free cash flow margin 7.55% 0.00% 0.00%
Return on equity (2.98%) 0.00% (0.40%)
Return on assets (1.46%) 0.00% (3.32%)
Return on invested capital 0.51% 0.00% 0.00%

Growth

Metric ELAN HLN Drug Manufacturers Specialty & Generic median
Revenue growth (TTM) 11.95% — 10.01%
EPS growth (last fiscal year) (169.12%) 22.50% —
Revenue growth, 5-year CAGR 7.59% 1.43% 6.74%
Net income growth, 5-year CAGR 0.00% 6.98% 0.00%

Health

Metric ELAN HLN Drug Manufacturers Specialty & Generic median
Debt to equity 0.59 0.50 0.05
Current ratio 2.05 0.69 2.31
Net debt to EBITDA 5.00 2.63 0.85

Dividend

Metric ELAN HLN Drug Manufacturers Specialty & Generic median
Dividend yield — 1.70% 1.70%
Payout ratio 0.00 — 0.00

Size

Metric ELAN HLN Drug Manufacturers Specialty & Generic median
Market cap 11.21b 40.28b 337.35m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack